WO2005046657A2 - Use of an inhibitor of csf-1 activity for the treatment of inflammatory bowel disease - Google Patents
Use of an inhibitor of csf-1 activity for the treatment of inflammatory bowel disease Download PDFInfo
- Publication number
- WO2005046657A2 WO2005046657A2 PCT/GB2004/004652 GB2004004652W WO2005046657A2 WO 2005046657 A2 WO2005046657 A2 WO 2005046657A2 GB 2004004652 W GB2004004652 W GB 2004004652W WO 2005046657 A2 WO2005046657 A2 WO 2005046657A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- csf
- antibody
- fragment
- inhibitor
- activity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/243—Colony Stimulating Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Definitions
- the present invention relates generally to methods of treating inflammatory bowel disease and more specifically to the use of inhibitors of CSF-1 activity for the manufacture of a medicament for the treatment of inflammatory bowel disease.
- the colony stimulating factor 1 also known as macrophage colony stimulating factor (M-CSF) is a cytokine produced by a variety of cells, including macrophages, endothelial cells and fibroblasts.
- CSF-1 is composed of two "monomer" polypeptides, which form a biologically active dimeric CSF-1 protein.
- CSF-1 exists in at least three mature forms due to alternative RNA splicing (see, Cerretti et al. Molecular
- CSF-1 The three forms of CSF-1 are translated from different rnRNA precursors, which encode polypeptide monomers of 256 to 554 amino acids, having a 32 amino acid signal sequence at the amino terminal and a putative transmembrane region of approximately 23 amino acids near the carboxyl terminal.
- the precursor peptides are subsequently processed by amino terminal and carboxyl terminal proteolytic cleavages to release mature CSF-1.
- Residues 1-149 of all three mature forms of CSF-1 are identical and are believed to contain sequences essential for biological activity of CSF-1.
- CSF-1 monomers are dimerized via disulfide-linkage and are glycosylated.
- CSF-1 belongs to a group of biological agonists that promote the production of blood cells. Specifically, it acts as a growth and differentiation factor for bone marrow progenitor cells of the mononuclear phagocyte lineage. Further, CSF-1 stimulates the proliferation and function of mature macrophages via specific receptors on responding cells.
- the CSF-1 receptor is also referred to as the c-fms gene product or CD115.
- IBD 'inflammatory bowel disease'
- IBD refers to serious, chronic disorders of the intestinal tract characterised by chronic inflammation at various sites in the gastrointestinal tract, and specifically includes ulcerative colitis (UC) and Crohn's disease (CD).
- LBD ulcerative colitis .
- This aberrant response is most likely facilitated by defects in both the barrier function of the intestinal epithelium and the mucosal immune system and both genetic and environmental factors are thought to contribute to susceptibility to LBD (Podolsky, 2002, N.Engl J.Med, 347,6, 417-429).
- Treatment of IBD typically begins with steroids and 5-aminosalicylic acid drugs, although there are problems associated with their long-term use.
- Thl cytokines are thought to activate macrophages, which in turn, produce interleukin-12, interleukin-18 and macrophage migration inhibitor factor and thus further stimulate Thl in a self-sustaining cycle.
- the activated macrophages produce a potent mix of inflammatory cytokines, including TNF, interleukin-1 and interleukin-6 (Podolsky, 2002, N.Engl.J.Med, 347, 417-429).
- the mucosa of patients with established CD is dominated by CD4+ lymphocytes with a type I helper-T-cell (Thl) phenotype characterised by increased expression of interferon ⁇ , interleukin (IL-)-2 followed by a subsequent increase in production of the proinflammatory cytokines TNF and IL- 1 ⁇ , and then NF- ⁇ B, as well as a compensatory increase in the Th2 mediated anti-inflammatory cytokine IL-10 and transforming growth factor ⁇ .
- Thl type I helper-T-cell
- the mucosa in patients may be dominated by CD4+ lymphocytes with an atypical type 2 helper-T-cell (Th2) phenotype, and a relatively decreased Thl response.
- the Th2 response is characterised by an increased expression of IL-4, IL-5, IL-6, IL- 10 and IL- 13.
- the many different cytokines and T-lymphocyte cell types implicated in LBD all represent potential targets for the treatment of IBD and many different treatments are in development whose targets include TNF, ⁇ 4 integrin, IL-2, IL-12, interferon ⁇ , ICAM-1 and CD-40 ligand (Sandborn, 2002, Gastroenterology, 122, 1592-1608). Whether CSF-1 plays any role in the pathogenesis of IBD is not known.
- CSF-1 is known to have a role in macrophage production in the intestine as mice that lack CSF-1 lose the resident intestinal macrophage population (Cecchini et al., 1994, Development, 120, 1357-1372). Increased CSF-1 serum levels have been observed in patients with active IBD, in comparison to patients in remission or healthy controls (Makiyama et al, Gastr ⁇ enterol. Jpn.1993, 28, 740).
- CSF-1 has been used in the treatment of immune suppression, in the treatment or prevention of bacterial, viral or fungal infections, the stimulation of white blood cells and in wound healing while inhibitors of CSF-1 have been used to treat tumor diseases (EP1223980).
- Inhibitors of CSF-1 activity are well known in the art, for example neutralising antibodies against CSF-1 and CSF-1R have been described (Weir et al., 1996, J Bone Miner. Res.ll, 1474-1481; Haran-Ghera et al, 1997, Blood, 89, 2537-2545) and antisense antagonists of CSF-1 have also been described (EP1223980).
- neutralising antibodies against CSF-1 and CSF-1R have been described (Weir et al., 1996, J Bone Miner. Res.ll, 1474-1481; Haran-Ghera et al, 1997, Blood, 89, 2537-2545) and antisense antagonists of CSF-1 have also been described (EP1223980).
- the present invention provides a method for the treatment and/or prophylaxis of LBD comprising administering a therapeutically effective amount of an inhibitor of CSF-1 activity.
- the invention also provides the use of an inhibitor of CSF-1 activity for the manufacture of a medicament for the treatment and or prophylaxis of inflammatory bowel disease.
- inflammatory bowel disease includes diseases that are characterised by chronic inflammation at various sites in the gastrointestinal tract.
- Illustrative inflammatory bowel diseases include but are not limited to regional enteritits (or Crohn's disease), idiopathic ulcerative colitis, idiopathic proctocolitis and infectious colitis.
- the term 'CSF-1 activity' as used herein refers to the spectrum of activity understood in the art for CSF-1, in particular the activity of human CSF-1 i.e. when applied to the standard in vitro colony stimulating assay of Metcalf, J.Cell.Physiol (1970) 76-89.
- An inhibitor of CSF-1 activity according to the present invention is an agent that interferes with the activity of CSF-1 in particular the activity of CSF-1 in IBD. Particularly preferred are agents which interfere with the activity of CSF-1 in JJBD in humans.
- Inhibitors according to the present invention may partially or completely inhibit CSF-1 activity.
- Inhibitors of use in the present invention include without limitation, inhibitors that are capable of interacting with (e.g. binding to, or recognising) CSF-1 or the CSF-1 receptor (CSF-1 R) or a nucleic acid molecule encoding CSF-1 or CSF-1 R, or are capable of inhibiting the expression of CSF-1 or CSF-1 R or are capable of inhibiting the interaction between CSF-1 and CSF-1R.
- Such inhibitors may be, without limitation, antibodies, nucleic acids (e.g. DNA, RNA, antisense RNA and siRNA), carbohydrates, lipids, proteins, polypeptides, peptides, peptidomimetics, small molecules and other drugs.
- Suitable inhibitors include, but are not limited to, a synthetic functional fragment of the CSF-1 receptor that binds to CSF-1 and interferes with binding to the native CSF-1 receptor, an antibody that binds to CSF-1 or to the CSF-1 receptor and interferes with CSF-1 receptor-ligand interaction, an antisense nucleic acid molecule that specifically hybridizes to mRNA encoding CSF-1 or the CSF receptor or a small molecule or other drug which inhibits the activity of CSF-1 or its receptor.
- Inhibitors of CSF-1 activity are well known in the art as are methods of identifying and producing such inhibitors. Neutralising anti-CSF-1 antibodies have been described, for example by Weir et al., 1996, J Bone Miner.
- Agents that may be suitable inhibitors can be selected from a wide variety of candidate agents.
- candidate agents include but are not limited to, nucleic acids (e.g. DNA and RNA), carbohydrates, lipids, proteins, polypeptides, peptides, peptidomimetics, small molecules and other drugs.
- Agents can be obtained using any of the numerous approaches in combinatorial library methods known in the art, including: biological libraries; spatially addressable parallel solid phase or solution phase libraries; synthetic library methods requiring deconvolution; the "one-bead one-compound” library method; and synthetic library methods using affinity chromatography selection.
- biological libraries is suited to peptide libraries, while the other four approaches are applicable to peptide, non-peptide oligomer or small molecule libraries of compounds (Lam, 1997, Anticancer Drug Des. 12:145; U.S. 5,738,996; and U.S. 5,807,683).
- the inhibitor for use in the present invention may be a nucleic acid.
- CSF-1 or CSF-1R nucleic acid molecules may be used as anti-sense molecules, to alter the expression of their respective polypeptides by binding to complementary nucleic acids.
- CSF-1 or CSF-1R nucleic acids may be obtained using standard cloning techniques from for example genomic DNA or cDNA or can be synthesised using well known and commercially available techniques.
- the CSF-1 or CSF-1R nucleic acids may contain one or more nucleotide substitutions, additions or deletions into the nucleotide sequence of a CSF-1 or CSF- 1 R nucleic acid. Standard techniques known to those of skill in the art can be used to introduce mutations, including, for example, site-directed mutagenesis and PCR-mediated mutagenesis.
- An antisense nucleic acid according to the present invention includes a CSF-1 or CSF-1R nucleic acid capable of hybridising by virtue of some sequence complementarity to a portion of an RNA (preferably mRNA) encoding the respective polypeptide.
- the antisense nucleic acid can be complementary to a coding and/or non-coding region of an mRNA encoding such a polypeptide.
- the antisense nucleic acids result in inhibition of the expression of the CSF-1 or CSF-1R polypeptide.
- the present invention provides a method for the treatment and/or prophylaxis of IBD comprising administering a therapeutically effective amount of an inhibitor of CSF-1 activity wherein the inhibitor comprises at least eight nucleotides that are antisense to a gene or cDNA encoding a CSF-1 or CSF-1R polypeptide.
- the invention also provides the use of nucleic acids comprising at least eight nucleotides that are antisense to a gene or cDNA encoding a CSF-1 or CSF-1R polypeptide for the manufacture of a medicament for use in the treatment and/or prophylaxis of LBD. Examples of suitable sequences are provided in EP1223980 and these are incorporated herein by reference.
- an inhibitor for use in the treatment and/or prophylaxis of LBD is an antibody that interacts with (i.e. binds to or recognises) CSF-1 or its receptor and inhibits the activity of CSF-1. Accordingly, there is provided the use of an antibody that inhibits the activity of CSF-1 for the manufacture of a medicament for use in the treatment and/or prophylaxis of LBD. Also provided is a method of treatment and or prophylaxis of LBD in a subject comprising administering to said subject a therapeutically effective amount of an antibody that inhibits the activity of CSF-1. In one example the antibodies selectively interact with CSF-1. Selectively interacting with (e.g.
- recognising or binding to means that the antibodies have a greater affinity for CSF-1 polypeptides than for other polypeptides.
- suitable antibodies are those that inhibit the activity of CSF-1 by binding to CSF-1 in such a manner as to prevent it being biologically active, for example by preventing the binding of CSF-1 to its receptor.
- an anti-CSF- 1 antibody for the manufacture of a medicament for use in the treatment and/or prophylaxis of IBD.
- a method of treatment and/or prophylaxis of LBD in a subject comprising administering to said subject a therapeutically effective amount of an anti-CSF- 1 antibody.
- the antibodies selectively interact with the CSF-1 receptor.
- Selectively interacting with means that the antibodies have a greater affinity for the CSF-1 receptor polypeptide than for other polypeptides.
- suitable antibodies are those that inhibit the activity of CSF-1 by preventing CSF-1 mediated signalling from the receptor, for example by preventing CSF-1 from binding to the CSF-1 receptor.
- an anti-CSF-lR antibody for the manufacture of a medicament for use in the treatment and/or prophylaxis of IBD.
- a method of treatment and or prophylaxis of IBD in a subject comprising administering to said subject a therapeutically effective amount of an anti-CSF- 1R antibody.
- CSF-1 or CSF-1 receptor polypeptides or cells expressing said polypeptides can be used to produce antibodies which specifically recognise said polypeptides.
- the CSF- 1 and CSF-1 R polypeptides may be 'mature' polypeptides or biologically active fragments or derivatives thereof.
- the CSF-1 polypeptide contains amino acids 1-149 believed to be important for biological activity.
- CSF-1 and CSF-1 R polypeptides may be prepared by processes well known in the art from genetically engineered host cells comprising expression systems or they may be recovered from natural biological sources.
- the term "polypeptides" includes peptides, polypeptides and proteins. These are used interchangeably unless otherwise specified.
- CSF-1 or CSF-1R polypeptides may in some instances be part of a larger protein such as a fusion protein for example fused to an affinity tag.
- Antibodies generated against these polypeptides may be obtained by administering the polypeptides to an animal, preferably a non-human animal, using well-known and routine protocols, see for example Handbook of Experimental Immunology, D. M. Weir (ed.), Vol 4, Blackwell Scientific Publishers, Oxford, England, 1986). Many warm-blooded animals, such as rabbits, mice, rats, sheep, cows or pigs may be immunized. However, mice, rabbits, pigs and rats are generally preferred.
- Anti-CSF- 1 and anti-CSF- 1 receptor antibodies for use in the present invention include whole antibodies and functionally active fragments or derivatives thereof and may be, but are not limited to, polyclonal, monoclonal, multi-valent, multi-specific, humanized or chimeric antibodies, single chain antibodies, Fab fragments, Fab' and F(ab') 2 fragments, fragments produced by a Fab expression library, anti-idiotypic (anti-Id) antibodies, and epitope-binding fragments of any of the above.
- Antibodies include immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e. molecules that contain an antigen binding site that specifically binds an antigen.
- the immunoglobulin molecules of the invention can be of any class (e.g. IgG, IgE, IgM, IgD and IgA) or subclass of immunoglobulin molecule.
- Monoclonal antibodies may be prepared by any method known in the art such as the hybridoma technique (Kohler & Milstein, 1975, Nature, 256:495-497), the trioma technique, the human B-cell hybridoma technique (Kozbor et al, 1983, Immunology Today, 4:72) and the EBV-hybridoma technique (Cole et al, Monoclonal Antibodies and Cancer Therapy, ⁇ p77-96, Alan R Liss, Inc., 1985).
- Antibodies for use in the invention may also be generated using single lymphocyte antibody methods by cloning and expressing immunoglobulin variable region cDNAs generated from single lymphocytes selected for the production of specific antibodies by for example the methods described by Babcook, J. et al, 1996, Proc. Natl. Acad. Sci. USA 93(15):7843-7848, WO92/02551 and WO2004051268.
- Humanized antibodies are antibody molecules from non-human species having one or more complementarity determining regions (CDRs) from the non-human species and a framework region from a human immunoglobulin molecule (see, e.g. US 5,585,089).
- Chimeric antibodies are those antibodies encoded by immunoglobulin genes that have been genetically engineered so that the light and heavy chain genes are composed of immunoglobulin gene segments belonging to different species. These chimeric antibodies are likely to be less antigenic.
- Bivalent antibodies may be made by methods known in the art (Milstein et al, 1983, Nature 305:537-539; WO 93/08829, Traunecker et al, 1991, EMBO J. 10:3655-3659). Multi-valent antibodies may comprise multiple specificities or may be monospecific (see for example WO 92/22853).
- the antibodies for use in the present invention can also be generated using various phage display methods known in the art and include those disclosed by Brinkman et al. (in J. Immunol.
- single chain antibodies such as those described in US 4,946,778 can also be adapted to produce single chain antibodies to CSF-1 or CSF-1R polypeptides.
- transgenic mice, or other organisms, including other mammals may be used to express humanized antibodies.
- Antibody fragments and methods of producing them are well known in the art, see for example Verma et al, 1998, Journal of hnmunological Methods, 216, 165-181.
- Particular examples of antibody fragments for use in the present invention are Fab' fragments which possess a native or a modified hinge region.
- modified hinge regions have already been described, for example, in US 5,677,425, WO9915549, and WO9825971 and these are incorporated herein by reference
- Further examples of particular antibody fragments for use in the present invention include those described in international patent applications PCT/GB2004/002810, PCT/GB2004/002870 and PCT/GB2004/002871 (all filed on 1 st July 2004).
- the modified antibody Fab fragments described in International patent application PCT/GB2004/002810 are preferred.
- an antibody for use in the present invention may be conjugated to one or more effector molecule(s).
- effector molecule includes, for example, antineoplastic agents, drugs, toxins, biologically active proteins, for example enzymes, other antibody or antibody fragments, synthetic or naturally occurring polymers, nucleic acids and fragments thereof e.g. DNA, RNA and fragments thereof, radionuclides, particularly radioiodide, radioisotopes, chelated metals, nanoparticles and reporter groups such as fluorescent compounds or compounds which may be detected by NMR or ESR spectroscopy.
- anti-CSF- 1 or anti CSF-1 R antibodies can be conjugated to an effector molecule, such as a cytotoxic agent, a radionuclide or drug moiety to modify a given biological response.
- the therapeutic agent may be a drug moiety which may be a protein or polypeptide possessing a desired biological activity.
- moieties may include, for example and without limitation, a toxin such as abrin, ricin A, pseudomonas exotoxin, or diphtheria toxin, a protein such as tumour necrosis factor, ⁇ -interferon, ⁇ - interferon, nerve growth factor, platelet derived growth factor or tissue plasminogen activator, a thrombotic agent or an anti-angio genie agent, e.g.
- angiostatin or endostatin or, a biological response modifier such as a lymphokine, interleukin-1 (IL-1), interleukin-2 (IL-2), interleukin-6 (IL-6), granulocyte macrophage colony stimulating factor (GM-CSF), granulocyte colony stimulating factor (G-CSF), nerve growth factor (NGF) or other growth factor.
- IL-1 interleukin-1
- IL-2 interleukin-2
- IL-6 interleukin-6
- GM-CSF granulocyte macrophage colony stimulating factor
- G-CSF granulocyte colony stimulating factor
- nerve growth factor NGF
- the effector molecules may be cytotoxins or cytotoxic agents including any agent that is detrimental to (e.g. kills) cells.
- Examples include taxol, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicin, doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, and puromycin and analogs or homologs thereof. Effector molecules also include, but are not limited to, antimetabolites (e.g.
- methotrexate 6- mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil decarbazine
- alkylating agents e.g. mechlorethamine, thioepa chlorambucil, melphalan, carmustine (BSNU) and lomustine (CCNU)
- cyclothosphamide busulfan, dibromomannitol, streptozotocin, mitomycin C, and cis-dichlorodiamine platinum (II) (DDP) cisplatin
- anthracyclines e.g. daunorubicin (formerly daunomycin) and doxorubicin
- antibiotics e.g.
- dactinomycin (formerly actinomycin), bleomycin, mithramycin, anthramycin (AMC), calicheamicins or duocarmycins), and anti-mitotic agents (e.g. vincristine and vinblastine).
- Other effector molecules may include radionuclides such as ⁇ In and 90 Y, Lu 177 , Bismuth 213 , Californium 252 , Iridium 192 and Tungsten 188 /Rhenium 188 ; or drugs such as but not limited to, alkylphosphocholines, topoisomerase I inhibitors, taxoids and suramin.
- the antibody or fragment thereof is fused via a covalent bond (e.g. a peptide bond), at optionally the N-terminus or the
- the antibody, or fragment thereof is linked to the other protein at the N-terminus of the constant domain of the antibody.
- Recombinant DNA procedures may be used to create such fusions, for example as described in WO 86/01533 and EP 0392745.
- the effector molecule may increase half-life in vivo, and/or decrease immunogenicity and/or enhance the delivery of an antibody across an epithelial barrier to the immune system.
- suitable effector molecules include polymers and proteins such as albumin and albumin binding proteins.
- suitable polymers include any synthetic or naturally occurring substantially water-soluble, substantially non- antigenic polymer including, for example, optionally substituted straight or branched chain polyalkylene, polyalkenylene, or polyoxyalkylene polymers or branched or unbranched polysaccharides, e.g. a homo- or hetero- polysaccharide such as lactose, amylose, dextran or glycogen.
- Particular optional substituents which may be present on the above-mentioned synthetic polymers include one or more hydroxy, methyl or methoxy groups.
- polystyrene resin examples include optionally substituted straight or branched chain poly(ethyleneglycol), poly(propyleneglycol), poly(vinylalcohol) or derivatives thereof, especially optionally substituted poly(ethyleneglycol) such as methoxypoly(ethyleneglycol).
- the polymer is a polyalkylene oxide such as polyethylene glycol (PEG).
- PEG polyethylene glycol
- antibodies for use in the present invention are attached to poly(ethyleneglycol) (PEG) moieties.
- the antibody is an antibody fragment and the PEG molecules may be attached through any available amino acid side- chain or terminal amino acid functional group located in the antibody fragment, for example any free amino, imino, thiol, hydroxyl or carboxyl group.
- Such amino acids may occur naturally in the antibody fragment or may be engineered into the fragment using recombinant DNA methods. See for example US 5,219,996.
- Multiple sites can be used to attach two or more PEG molecules.
- PEG molecules are covalently linked through a thiol group of at least one cysteine residue located in the antibody fragment. Where a thiol group is used as the point of attachment appropriately activated effector molecules, for example thiol selective derivatives such as maleimides and cysteine derivatives may be used.
- the antibody is a modified Fab fragment which is PEGylated, i.e. has PEG (poly(ethyleneglycol)) covalently attached thereto, e.g.
- the total amount of PEG attached to the fragment may be varied as desired, but will generally be in an average molecular weight range from 250 to 100,000Da, preferably from 5,000 to 5O,00ODa, more preferably from 10,000 to 40,000Da and still more preferably from 20,000 to 40,000Da.
- the size of PEG may in particular be selected on the basis of the intended use of the product, for example ability to localize to certain tissues such as tumors or extend circulating half-life (for review see Chapman, 2002, Advanced Drug Delivery Reviews, 54, 531-545).
- the antibody is a modified Fab' fragment and PEG is attached to a cysteine in the hinge region.
- a PEG modified Fab' fragment has a maleimide group covalently linked to a single thiol group in a modified hinge region.
- a lysine residue may be covalently linked to the maleimide group and to each of the amine groups on the lysine residue may be attached a methoxypoly(ethyleneglycol) polymer having a molecular weight of approximately 20,000 Da.
- the total molecular weight of the PEG attached to the Fab' fragment may therefore be approximately 40,000 Da.
- an antibody fragment for use in the present invention is a PEGylated (i.e.
- PEG poly(ethyleneglycol) covalently attached thereto
- Fab fragment as described in International Application Number PCT/GB2004/002810 (filed on 1 st July 2004).
- the PEGylated Fab fragment has PEG attached to each interchain cysteine.
- each PEG attached to an interchain cysteine has a molecular weight of 20,000Da and the total molecular weight of the PEG attached to the Fab fragment is 40,000Da.
- inhibitors are identified by first identifying agents that interact with CSF-1 or CSF-1R and subsequently testing those agents to identify those that inhibit CSF-1 activity.
- the agent is an antibody.
- Agents that interact with CSF-1 or CSF1-R may be identified using any suitable method, for example by using a cell-free or cell-based assay system where the CSF-1 or CSF-1R polypeptide is contacted with a candidate agent and the ability of the candidate agent to interact with the polypeptide is determined.
- the ability of a candidate agent to interact with a CSF-1 or CSF-1R polypeptide is compared to a reference range or control. If desired, this assay may be used to screen a plurality (e.g. a library) of candidate agents using a plurality of CSF-1 or CSF-1R polypeptide samples.
- a first and second sample comprising native or recombinant CSF-1 or CSF-1R polypeptide are contacted with a candidate agent or a control agent and the ability of the candidate agent to interact with the polypeptide is determined by comparing the difference in interaction between the candidate agent and control agent.
- the polypeptide is first immobilized, by, for example, contacting the polypeptide with an immobilized antibody which specifically recognizes and binds it, or by contacting a purified preparation of polypeptide with a surface designed to bind proteins.
- the polypeptide may be partially or completely purified (e.g. partially or completely free of other polypeptides) or part of a cell lysate.
- polypeptide may be a fusion protein comprising the CSF-1 or CSF1-R polypeptide or a biologically active portion thereof and a domain such as glutathionine-S- transferase or the Fc region of IgGl .
- polypeptide can be biotinylated using techniques well known to those of skill in the art (e.g. biotinylation kit, Pierce Chemicals; Rockford, IL).
- biotinylation kit Pierce Chemicals; Rockford, IL
- the ability of the candidate agent to interact with the polypeptide can be determined by methods known to those of skill in the art for example, ELIS A, BIAcoreTM, Flow cytometry or fluorescent microvolume assay technology (FMAT).
- a population of cells expressing CSF-1 or CSF-1 R is contacted with a candidate agent and the ability of the candidate agent to interact with the polypeptide is determined.
- the ability of a candidate agent to interact with CSF-1 or CSF-1 R is compared to a reference range or control.
- the cell for example, can be of eukaryotic origin (e.g. yeast or mammalian) and can express the CSF-1 or CSF-1 R polypeptide endogenously or be genetically engineered to express the polypeptide.
- the CSF-1 or CSF-1R polypeptide or the candidate agent is labelled, for example with a radioactive label (such as P, S or I) or a fluorescent label (such as fluorescein isothiocyanate, rhodamine, phycoerythrin, phycocyanin, allophycocyanin, o-phthaldehyde or fluorescamine) to enable detection of an interaction between a polypeptide and a candidate agent.
- a radioactive label such as P, S or I
- a fluorescent label such as fluorescein isothiocyanate, rhodamine, phycoerythrin, phycocyanin, allophycocyanin, o-phthaldehyde or fluorescamine
- Alternative methods such as ELISA, flow cytometry and FMAT may also be used.
- Agents which inhibit CSF-1 activity may be identified by any suitable method, for example by: (i) comparing the activity of CSF- 1 in the presence of a candidate agent with the activity of said polypeptide in the absence of the candidate agent or in the presence of a control agent; and (ii) determining whether the candidate agent inhibits activity of CSF-1
- Such assays can be used to screen candidate agents, in clinical monitoring or in drug development.
- agents may be pre-screened where appropriate (e.g. an antibody) to identify agents that interact with CSF-1 or CSF-1R prior to screening those agents which bind for their ability to inhibit CSF-1 activity.
- a cell-based assay system is used to identify agents capable of inhibiting the activity of CSF-1.
- the assay used to identify inhibitors of CSF-1 activity is the standard in vitro colony stimulating assay of Metcalf, 1970, J. Cell.Physiol.76-89 in which CSF-1 is capable of stimulating the formation of macrophage colonies.
- Potential inhibitors are added to the assay and proliferation of macrophages is measured by any suitable method such as 3 H thymidine incorporation or formazan dye conversion. Inhibition is therefore measured as a reduction in proliferation compared to controls.
- inhibitors of CSF-1 may down-regulate the expression of the CSF-1 or CSF-1R polypeptide, for example antisense inhibitors.
- Such inhibitors may be identified by any method known in the art. In one example such inhibitors are identified in a cell-based assay system.
- a population of cells expressing a CSF-1 or CSF-R polypeptide or nucleic acid are contacted with a candidate agent and the ability of the candidate agent to alter expression of the CSF-1 or CSF-1R polypeptide or nucleic acid is determined by comparison to a reference range or control.
- populations of cells expressing a CSF-1 or CSF1-R polypeptide are contacted with a candidate agent or a control agent and the ability of the candidate agent to alter the expression of the CSF-1 or CSF-1R polypeptides or nucleic acids is determined by comparing the difference in the level of expression of the CSF-1 or CSF1-R polypeptides or nucleic acids between the treated and control populations of cells.
- this assay may be used to screen a plurality (e.g. a library) of candidate agents.
- the cell for example, can be of eukaryotic origin (e.g. yeast or mammalian) and can express a CSF-1 or CSF-1R polypeptide endogenously or be genetically engineered to express a CSF-1 or CSF- 1R polypeptide.
- the ability of the candidate agents to alter the expression of a said polypeptides or nucleic acids can be determined by methods known to those of skill in the art, for example and without limitation, by flow cytometry, radiolabelling, a scintillation assay, immunoprecipitation, Western blot analysis, Northern blot analysis or RT-PCR.
- Agents that inhibit the activity of CSF-1 may be identified or further tested, for example to determine therapeutically effective amounts in one or more animal models.
- suitable animals include, but are not limited to, mice, rats, rabbits, monkeys, guinea pigs, dogs and cats.
- the animal used represents a model of LBD.
- a first and second group of mammals are administered with a candidate agent or a control agent and the ability of the candidate agent to inhibit the expression of CSF-1 or CSF-1R polypeptide or nucleic acid is determined by comparing the difference in the level of expression between the first and second group of mammals.
- the expression levels of the CSF-1 or CSF-1R polypeptides or nucleic acid in the first and second groups of mammals can be compared to the level of CSF-1 or CSF-1R polypeptide or nucleic acid in a control group of mammals.
- the candidate agent or a control agent can be administered by means known in the art (e.g. orally, rectally or parenterally such as intraperitoneally or intravenously). Changes in the expression of a polypeptide or nucleic acid can be assessed by the methods outlined above.
- the inhibition of CSF-1 activity can be determined by monitoring an amelioration or improvement in disease symptoms, a delayed onset or slow progression of the disease, for example but without limitation, a reduction in weight loss or diarrhoea.
- the different models tend to show signs of colitis such as weight loss and diarrhoea with or without the presence of blood.
- the intestines will usually show an inflammatory infiltrate and the extent of this and the exact site of disease can vary between models.
- the symptoms that are measured during treatment will therefore vary between models but will typically include measuring weight loss or the presence of diarrhoea and may also include looking for histological improvements, such as reduced inflammatory infiltrate or reduced damage to the crypts.
- inhibitors of CSF-1 activity can be used in the treatment and/or prophylaxis of LBD.
- the agents will generally be administered in the form of a pharmaceutical composition.
- composition comprising an inhibitor of CSF- 1 activity and a pharmaceutically acceptable diluent, excipient and /or carrier.
- treatment' includes either therapeutic or prophylactic therapy.
- a reference is made herein to a method of treating or preventing a disease or condition using a particular inhibitor or combination of inhibitors, it is to be understood that such a reference is intended to include the use of that inhibitor or combination of inhibitors for the manufacture of a medicament for the treatment and/or prophylaxis of IBD.
- the composition will usually be supplied as part of a sterile, pharmaceutical composition that will normally include a pharmaceutically acceptable carrier. This composition may be in any suitable form (depending upon the desired method of administering it to a patient).
- the inhibitors of use in the invention are preferably administered to a subject orally or intrarectally but may also be administered by a variety of other routes such as transdermally, subcutaneously, intranasally, intravenously and intramuscularly.
- routes such as transdermally, subcutaneously, intranasally, intravenously and intramuscularly.
- the most suitable route for administration in any given case will depend on the particular inhibitor, the subject, and the nature and severity of the disease and the physical condition of the subject.
- the inhibitors of use in the invention may be administered in combination, e.g. simultaneously, sequentially or separately, with one or more other therapeutically active compounds, which may be for example other anti-LBD therapies or anti-cancer therapies.
- Pharmaceutical compositions maybe conveniently presented in unit dose forms containing a predetermined amount of an active agent of the invention per dose.
- Such a unit may contain for example but without limitation, 750mg/kg to O.lmg/kg depending on the condition being treated, the route of administration and the age, weight and condition of the subject.
- Pharmaceutically acceptable carriers for use in the invention may take a wide variety of forms depending, e.g. on the route of administration.
- Compositions for oral administration may be liquid or solid.
- Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use.
- Oral liquid preparations may contain suspending agents as known in the art.
- oral solid preparations such as powders, capsules and tablets
- carriers such as starches, sugars, microcrystalline cellulose, granulating agents, lubricants, binders, disintegrating agents, and the like may be included. Because of their ease of administration, tablets and capsules represent the most advantageous oral dosage unit form in which case solid pharmaceutical carriers are generally employed.
- active agents of the invention may also be administered by controlled release means and/or delivery devices.
- Tablets and capsules may comprise conventional carriers or excipients such as binding agents for example, syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrrolidone; fillers, for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tableting lubricants, for example magnesium stearate, talc, polyethylene glycol or silica; disintegrants, for example potato starch; or acceptable wetting agents such as sodium lauryl sulphate.
- the tablets may be coated by standard aqueous or non-aqueous techniques according to methods well known in normal pharmaceutical practice.
- compositions of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets, each containing a predetermined amount of the active agent, as a powder or granules, or as a solution or a suspension in an aqueous liquid, a non-aqueous liquid, an oil-in-water emulsion or a water- in-oil liquid emulsion.
- Such compositions may be prepared by any of the methods of pharmacy but all methods include the step of bringing into association the active agent with the carrier, which constitutes one or more necessary ingredients.
- the compositions are prepared by uniformly and intimately admixing the active agent with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product into the desired presentation.
- a tablet may be prepared by compression or moulding, optionally with one or more accessory ingredients.
- Pharmaceutical compositions suitable for parenteral administration may be prepared as solutions or suspensions of the active agents of the invention in water suitably mixed with a surfactant such as hydroxypropylcellulose.
- Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms .
- the pharmaceutical forms suitable for injectable use include aqueous or non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the composition isotonic with the blood of the intended recipient, and aqueous and non-aqueous sterile suspensions which may include suspending agents and tWckening agents.
- aqueous or non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the composition isotonic with the blood of the intended recipient
- aqueous and non-aqueous sterile suspensions which may include suspending agents and tWckening agents.
- Extemporaneous injection solutions, dispersions and suspensions may be prepared from sterile powders, granules and tablets.
- Pharmaceutical compositions can be administered with medical devices known in the art.
- a pharmaceutical composition of the invention can be administered with a needleless hypodermic injection device, such as the devices disclosed in US 5,399,163; 5,383,851; 5,312,335; 5,064,413; 4,941,880; 4,790,824; or 4,596,556.
- a needleless hypodermic injection device such as the devices disclosed in US 5,399,163; 5,383,851; 5,312,335; 5,064,413; 4,941,880; 4,790,824; or 4,596,556.
- Examples of well-known implants and modules useful in the present invention include: US 4,487,603, which discloses an implantable micro-infusion pump for dispensing medication at a controlled rate; US 4,486,194, which discloses a therapeutic device for administering medicaments through the skin; US 4,447,233, which discloses a medication infusion pump for delivering medication at a precise infusion rate; US 4,447,224, which discloses a variable flow implantable infusion apparatus for continuous drug delivery; US 4,439,196, which discloses an osmotic drug delivery system having multi-chamber compartments; and US 4,475,196, which discloses an osmotic drug delivery system. Many other such implants, delivery systems, and modules are known to those skilled in the art.
- compositions adapted for topical administration may be formulated as ointments, creams, suspensions, lotions, powders, solutions, pastes, gels, impregnated dressings, sprays, aerosols or oils, transdermal devices, dusting powders, and the like.
- These compositions may be prepared via conventional methods containing the active agent.
- they may also comprise compatible conventional carriers and additives, such as preservatives, solvents to assist drug penetration, emollients in creams or ointments and ethanol or oleyl alcohol for lotions.
- Such carriers may be present as from about 1% up to about 98% of the composition. More usually they will form up to about 80% of the composition.
- compositions adapted for transdermal administration may be presented as discrete patches intended to remain in intimate contact with the epidermis of the recipient for a prolonged period of time.
- the active agent may be delivered from the patch by iontophoresis.
- the compositions are preferably applied as a topical ointment or cream.
- the active agent When formulated in an ointment, the active agent may be employed with either a paraffinic or a water-miscible ointment base. Alternatively, the active agent may be formulated in a cream with an oil-in-water cream base or a water-in-oil base.
- Pharmaceutical compositions adapted for topical administration in the mouth include lozenges, pastilles and mouth washes.
- Pharmaceutical compositions adapted for topical administration to the eye include eye drops wherein the active agent is dissolved or suspended in a suitable carrier, especially an aqueous solvent. They also include topical ointments or creams as above.
- Pharmaceutical compositions suitable for rectal administration wherein the carrier is a solid are most preferably presented as unit dose suppositories.
- Suitable carriers include cocoa butter or other glyceride or materials commonly used in the art, and the suppositories may be conveniently formed by admixture of the combination with the softened or melted ca ⁇ ier(s) followed by chilling and shaping moulds. They may also be administered as enemas.
- the dosage to be administered of an inhibitor of CSF-1 activity will vary according to the particular inhibitor, the type of IBD, the subject, and the nature and severity of the disease and the physical condition of the subject, and the selected route of administration; the appropriate dosage can be readily determined by a person skilled in the art.
- compositions comprising antibodies can be administered to patients (e.g., human subjects) at therapeutically or prophylactically effective dosages (e.g. dosages which result in inhibition of LBD and/or relief of IBD symptoms) using any suitable route of administration, such as injection and other routes of administration known in the art for clinical products, such as antibody-based clinical products.
- the compositions may contain from 0.1% by weight, preferably from 10-60%, or more, by weight, of the inhibitor of the invention, depending on the method of administration.
- an inhibitor of the invention will be determined by the nature and extent of the condition being treated, the form, route and site of administration, and the age and condition of the particular subject being treated, and that a physician will ultimately determme appropriate dosages to be used. This dosage may be repeated as often as appropriate. If side effects develop the amount and/or frequency of the dosage can be altered or reduced, in accordance with normal clinical practice.
- the inhibitor is a nucleic acid this may be administered via gene therapy (see for example Hoshida, T. et al, 2002, Pancreas, 25:111-121; Ikuno, Y. 2002, Invest. Ophthalmol. Vis. Sci.
- Gene therapy refers to administration to a subject of an expressed or expressible nucleic acid, hi one example this is either the CSF-1 or the CSF-IR nucleic acid or portions thereof. Any of the methods for gene therapy available in the art can be used according to the present invention. Delivery of the therapeutic nucleic acid into a patient can be direct in vivo gene therapy (i.e. the patient is directly exposed to the nucleic acid or nucleic acid-containing vector) or indirect ex vivo gene therapy (i.e. cells are first transformed with the nucleic acid in vitro and then transplanted into the patient).
- an expression vector containing the CSF-1 or CSF-IR nucleic acid may be administered in such a manner that it becomes intracellular, i.e. by infection using a defective or attenuated retroviral or other viral vectors as described, for example, in US 4,980,286 or by Robbins et al, 1998, Pharmacol. Ther. 80:35-47.
- the various retroviral vectors that are known in the art are such as those described in Miller et al. (1993, Meth. Enzymol. 217:581-599) which have been modified to delete those retroviral sequences which are not required for packaging of the viral genome and subsequent integration into host cell DNA.
- adenoviral vectors can be used which are advantageous due to their ability to infect non-dividing cells and such high-capacity adenoviral vectors are described in Kochanek (1999, Human Gene Therapy, 10:2451-2459).
- Chimeric viral vectors that can be used are those described by Reynolds et al. (1999, Molecular Medicine Today, 1:25 -31).
- Hybrid vectors can also be used and are described by Jacoby et al. (1997, Gene Therapy, 4:1282-1283).
- Direct injection of naked DNA or through the use of microparticle bombardment (e.g. Gene Gun®; Biolistic, Dupont) or by coating it with lipids can also be used in gene therapy.
- Cell-surface receptors/transfecting compounds or through encapsulation in liposomes, microparticles or microcapsules or by administering the nucleic acid in linkage to a peptide which is known to enter the nucleus or by administering it in linkage to a ligand predisposed to receptor-mediated endocytosis can be used to target cell types which specifically express the receptors of interest.
- a gene is transferred into cells in vitro using tissue culture and the cells are delivered to the patient by various methods such as injecting subcutaneously, application of the cells into a skin graft and the intravenous injection of recombinant blood cells such as haematopoietic stem or progenitor cells.
- Cells into which a CSF-1 or CSF-IR nucleic acid can be introduced for the purposes of gene therapy include, for example, epithelial cells, endothelial cells, keratinocytes, fibroblasts, muscle cells, hepatocytes and blood cells.
- the blood cells that can be used include, for example, T-lymphocytes, B-lymphocytes, monocytes, macrophages, neutrophils, eosinophils, megakaryotcytes, granulocytes, haematopoietic cells or progenitor cells, and the like.
- the pharmaceutical composition of the present invention comprises a CSF-1 or CSF-IR nucleic acid, said nucleic acid being part of an expression vector that expresses a CSF1 or CSF-IR polypeptide or chimeric protein thereof in a suitable host.
- such a nucleic acid has a promoter operably linked to the polypeptide coding region, said promoter being inducible or constitutive (and, optionally, tissue-specific).
- Figure 1 Effect of anti-CSF-1 antibody on body weight of mice after addition of DSS (1%) in drinking water. Statistical analysis by ANOVA with Bonferroni's post test:- **P ⁇ 0.01, ***P ⁇ 0.001 control antibody (101.4) vs. normal animals. #P ⁇ 0.05, ##P ⁇ 0.01, ###P ⁇ 0.001 101.4 vs. anti CSF-1.
- Figure 2. Effect of anti-CSF-1 antibody on colon length of mice after addition of DSS (1%) in drinking water for 8 days. Statistical analysis by ANOVA with Bonferroni's post test.
- Figure 3b Effect of anti-CSF-1 antibody on clinical disease severity score of mice after addition of DSS (1%) in drinking water.
- Figure 4a Effect of anti-CSF-1 antibody on GR1 high+ CD45+cells/mm in lamina intestinal population from colons of mice on day 8 after DSS(1%). Statistical analysis by ANOVA with Bonfenoni's post test.
- Figure 4b Effect of anti-CSF-1 antibody on CD3+ CD45+ cells/mm in lamina propria population from colons of mice on day 8, after DSS (1%). Statistical analysis by ANOVA with Bonferroni's post test.
- Figure 5 Effect of anti-CSF-1 antibody on CD3+ cell count from colons of mice on day 8 after DSS(1%). Statistical analysis by ANOVA with Bonferroni's post test.
- Figure 6. Effect of anti-CSF-1 antibody on F4/80+ cell count from colons of mice on day 8, after DSS(1%). Statistical analysis by ANOVA with Bonfenoni's post test.
- Example 1 Isolation of an anti-CSF-1 antibody Rabbits were immunised with mouse CSF-1 and using a haemolytic plaque assay with biotinylated sheep red blood cells coated with murine CSF-1 via streptavidin, 15 antibody genes were isolated using the methods described by Babcook et al, 1996, Proc.Natl.Acad.Sci, 93, 7843-7848 and in WO92/02551. The antibody genes were expressed in CHO cells and the recombinant antibodies screened for their ability to neutralise murine CSF-1 in a M-NFS-60 cell proliferation assay (Metcalf, J.Cell.Physiol (1970) 76-89).
- M-NFS-60 is a mouse macrophage cell line that is dependent on CSF-1 for growth.
- One antibody which neutralised CSF-1 activity was selected, mCSF1033 and a chimeric IgG (Ab33) produced using the rabbit variable regions from antibody mCSF1033 and mouse constant regions.
- the free cysteine residue in the rabbit variable region was alkylated using iodoacetamide (Pierce). This chimeric antibody was then used for testing in in vivo mouse models of LBD.
- the dextran sulfate sodium (DSS) model used was essentially as described in Cooper et al, 1993, Laboratory Investigation, 69, 238-249.
- Two groups of 10 male Balb/c mice were weighed and injected subcutaneously with either Ab33 (see Example 1) or a control antibody 101.4 (mouse anti-human TNFalpha antibody) at 1 Omg/kg. Normal drinking water was then replaced with 1% DSS in tap water 24 hours after the first antibody injection. Subsequent injections of antibodies at the same concentration were given once a week.
- a third group of 10 male Balb/c mice received no treatment and continued to receive normal drinking water.
- the sections were treated with Avidin D blocking solution for 15 minutes, rinsed briefly with buffer then incubated for 15 minutes with the biotin blocking solution (Vector Laboratories).
- the tissue sections were blocked with 20% normal donkey serum (Jackson ImmunoResearch Laboratories, Inc.) in TBS for 20 minutes at room temperature in order to reduce background signals caused by IgG Fc interactions by the biotinylated second step donkey reagent.
- the primary antibody was a polyclonal goat anti-mouse CD3 (Autogen Bioclear) diluted 1 :800 in 0.05M Tris buffered saline pH 7.6 (TBS). The sections were incubated for 60 minutes at room temperature.
- the CD3 values were determined by one blinded observer by means of an eyepiece graticule and assessed from areas along the colonic lamina intestinal. The number of CD3 positive cells within each selected area was counted at a magnification of x400 (10/animal). Grid area at x400 conesponds to 0.059mm 2 of tissue.
- the immunohistochemical method for the analysis of F4/80 positive staining cells was perfonned in the same way as for the CD3 analysis, in this case the tissue sections were blocked with 20%) normal rabbit serum (DakoCytomation) in TBS for 20 minutes at room temperature in order to reduce background signals caused by IgG Fc interactions by the biotinylated second step rabbit reagent.
- the primary antibody was a monoclonal rat anti-mouse F4/80 (Serotec) diluted 1:100 in 0.05M Tris buffered saline pH 7.6 (TBS). The sections were incubated for 60 minutes at room temperature. Thereafter the slides were incubated for 30 minutes at room temperature with biotinylated rabbit anti-rat antibody (DakoCytomation) diluted 1 :200 in TBS. The method was then the same as for the CD3 positive cell analysis
- Figure 1 shows following statistical analysis by ANOVA with Bonferroni's post test that there was no significant difference between anti-CSF-1 treated mice and normal control mice indicating that the anti-CSF-1 antibody had prevented the weight loss that normally occurs in DSS-induced colitis (see control antibody 101.4).
- Figure 2 shows that anti-CSF-1 also had a significant effect on colon length. The length of the colon is significantly reduced in mice with DSS-induced colitis and this is thought to reflect the extent of colonic inflammation. A protection from colon shortening was noted in mice treated with anti-CSF-1 antibody which had a significantly longer colon length than those treated with the negative control antibody 101.4.
- FIGs 3a and 3b show that anti-CSF-1 antibody also reduced the colonic disease severity score (signs of disease such as diarrhoea and rectal bleeding) and overall clinical disease score (a combination of colonic disease and weight loss).
- FACS analysis of colonic tissue is shown in Figures 4a and 4b.
- the number of neutrophils (GR1+ CD45+ cells) and T cells (CD3+ CD45+ cells) infiltrating the colon were found to be significantly increased in mice with DSS-induced colitis and treated with the 101.4 negative control antibody, whereas those mice treated with anti-CSF- 1 did not have significantly increased numbers of neutrophils or T cells compared with normal control mice.
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2004289098A AU2004289098B2 (en) | 2003-11-05 | 2004-11-03 | Use of an inhibitor of CSF-1 activity for the treatment of inflammatory bowel disease |
JP2006537439A JP2007510639A (en) | 2003-11-05 | 2004-11-03 | Method for treating inflammatory bowel disease |
EP04798381.2A EP1686970B1 (en) | 2003-11-05 | 2004-11-03 | Use of an inhibitor of CSF-1 activity for the treatment of Crohn's disease or ulcerative colitis |
CA002543926A CA2543926A1 (en) | 2003-11-05 | 2004-11-03 | Use of an inhibitor of csf-1 activity for the treatment of inflammatory bowel disease |
ES04798381T ES2733818T3 (en) | 2003-11-05 | 2004-11-03 | Use of a CSF-1 activity inhibitor for the treatment of Crohn's disease or ulcerative colitis |
US10/578,384 US20070148172A1 (en) | 2003-11-05 | 2004-11-03 | Method for the treatment of inflammatory bowel disease |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0325836.5 | 2003-11-05 | ||
GBGB0325836.5A GB0325836D0 (en) | 2003-11-05 | 2003-11-05 | Biological products |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005046657A2 true WO2005046657A2 (en) | 2005-05-26 |
WO2005046657A3 WO2005046657A3 (en) | 2005-11-03 |
Family
ID=29725999
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2004/004652 WO2005046657A2 (en) | 2003-11-05 | 2004-11-03 | Use of an inhibitor of csf-1 activity for the treatment of inflammatory bowel disease |
Country Status (8)
Country | Link |
---|---|
US (1) | US20070148172A1 (en) |
EP (1) | EP1686970B1 (en) |
JP (1) | JP2007510639A (en) |
AU (1) | AU2004289098B2 (en) |
CA (1) | CA2543926A1 (en) |
ES (1) | ES2733818T3 (en) |
GB (1) | GB0325836D0 (en) |
WO (1) | WO2005046657A2 (en) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011070024A1 (en) | 2009-12-10 | 2011-06-16 | F. Hoffmann-La Roche Ag | Antibodies binding preferentially human csf1r extracellular domain 4 and their use |
WO2011107553A1 (en) | 2010-03-05 | 2011-09-09 | F. Hoffmann-La Roche Ag | Antibodies against human csf-1r and uses thereof |
WO2011131407A1 (en) | 2010-03-05 | 2011-10-27 | F. Hoffmann-La Roche Ag | Antibodies against human csf-1r and uses thereof |
WO2013011021A1 (en) | 2011-07-18 | 2013-01-24 | The University Of Melbourne | Use of c-fms antagonists |
WO2013087699A1 (en) | 2011-12-15 | 2013-06-20 | F. Hoffmann-La Roche Ag | Antibodies against human csf-1r and uses thereof |
WO2013132044A1 (en) | 2012-03-08 | 2013-09-12 | F. Hoffmann-La Roche Ag | Combination therapy of antibodies against human csf-1r and uses thereof |
WO2014173814A1 (en) | 2013-04-22 | 2014-10-30 | F. Hoffmann-La Roche Ag | Combination therapy of antibodies against human csf-1r and tlr9 agonist |
CN102702358B (en) * | 2008-03-14 | 2016-02-17 | 天士力创世杰(天津)生物制药有限公司 | For the antibody of CSF-1R |
WO2016196679A1 (en) * | 2015-06-02 | 2016-12-08 | Genentech, Inc. | Compositions and methods for using anti-il-34 antibodies to treat neurological diseases |
EP3108897A1 (en) | 2015-06-24 | 2016-12-28 | F. Hoffmann-La Roche AG | Antibodies against human csf-1r for use in inducing lymphocytosis in lymphomas or leukemias |
US9856316B2 (en) | 2013-04-12 | 2018-01-02 | Morphosys Ag | Antibodies targeting M-CSF |
WO2018036852A1 (en) | 2016-08-25 | 2018-03-01 | F. Hoffmann-La Roche Ag | Intermittent dosing of an anti-csf-1r antibody in combination with macrophage activating agent |
WO2018115051A1 (en) | 2016-12-22 | 2018-06-28 | F. Hoffmann-La Roche Ag | Treatment of tumors with an anti-csf-1r antibody in combination with an anti-pd-l1 antibody after failure of anti-pd-l1/pd1 treatment |
WO2022238386A1 (en) | 2021-05-10 | 2022-11-17 | Institut Curie | Methods for the treatment of cancer, inflammatory diseases and autoimmune diseases |
US11512133B2 (en) | 2013-09-12 | 2022-11-29 | Hoffmann-La Roche Inc. | Methods for treating colon cancer or inhibiting cell proliferation by administering a combination of antibodies against human CSF-1R and antibodies against human PD-L1 |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010062401A2 (en) * | 2008-11-26 | 2010-06-03 | Five Prime Therapeutics, Inc. | Treatment of osteolytic disorders and cancer using csf1r extracellular domain fusion molecules |
WO2010062399A2 (en) * | 2008-11-26 | 2010-06-03 | Five Prime Therapeutics, Inc. | Csf1r extracellular domain fusion molecules and treatments using same |
EP3943154A1 (en) * | 2010-05-04 | 2022-01-26 | Five Prime Therapeutics, Inc. | Antibodies that bind csf1r |
US20130302322A1 (en) | 2012-05-11 | 2013-11-14 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
CN104684582A (en) | 2012-08-31 | 2015-06-03 | 戊瑞治疗有限公司 | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
JP6964410B2 (en) | 2014-06-23 | 2021-11-10 | ファイヴ プライム セラピューティクス インク | How to treat a disease with an antibody that binds to the colony stimulating factor 1 receptor (CSF1R) |
TWI711463B (en) | 2014-10-29 | 2020-12-01 | 美商戊瑞治療有限公司 | Combination therapy for cancer |
BR112017013111A2 (en) | 2014-12-22 | 2018-05-15 | Five Prime Therapeutics Inc | methods of treating a disorder and treating synovitis, use of an antibody and antibody |
PT3283527T (en) | 2015-04-13 | 2021-03-03 | Five Prime Therapeutics Inc | Combination therapy for cancer |
KR20200051024A (en) | 2017-09-13 | 2020-05-12 | 파이브 프라임 테라퓨틱스, 인크. | Combination anti-CSF1R and anti-PD-1 antibody combination therapy for pancreatic cancer |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5932595A (en) * | 1995-12-20 | 1999-08-03 | Syntex (U.S.A.) Inc. | Matrix metalloprotease inhibitors |
WO1999043839A1 (en) * | 1998-02-27 | 1999-09-02 | The Trustees Of The University Of Pennsylvania | Vaccines, immunotherapeutics and methods for using the same |
WO2000067777A1 (en) * | 1999-05-07 | 2000-11-16 | Biofan Pty Ltd | A method of prophylaxis and treatment and agents useful therefor |
WO2001030381A2 (en) * | 1999-10-28 | 2001-05-03 | Hofbauer, Reinhold | Use of csf-1 inhibitors |
WO2002087496A2 (en) * | 2001-04-30 | 2002-11-07 | Cedars-Sinai Medical Center | Methods for inhibiting macrophage colony stimulating factor and c-fms-dependent cell signaling |
WO2003020698A2 (en) * | 2001-09-06 | 2003-03-13 | Prochon Biotech Ltd. | Protein tyrosine kinase inhibitors |
WO2005010009A1 (en) * | 2003-07-24 | 2005-02-03 | Abbott Laboratories | Thienopyridine and furopyridine kinase inhibitors |
WO2005012226A1 (en) * | 2003-05-23 | 2005-02-10 | Mediquest Therapeutics, Inc. | Immunomodulation with novel pharmaceutical compositions |
WO2005030124A2 (en) * | 2003-09-10 | 2005-04-07 | Warner-Lambert Company Llc | Antibodies to m-csf |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4475196A (en) * | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
US4447233A (en) * | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
US4439196A (en) * | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
US4447224A (en) * | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
US4487603A (en) * | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
US4486194A (en) * | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
US4596556A (en) * | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
US4980286A (en) * | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
US4946778A (en) * | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US4790824A (en) * | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
US4941880A (en) * | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
US5677425A (en) * | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
GB8720833D0 (en) * | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
US5223409A (en) * | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5312335A (en) * | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
US5064413A (en) * | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
US5780225A (en) * | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
US5427908A (en) * | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9015198D0 (en) * | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5698426A (en) * | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
DE69129154T2 (en) * | 1990-12-03 | 1998-08-20 | Genentech Inc | METHOD FOR ENRICHING PROTEIN VARIANTS WITH CHANGED BINDING PROPERTIES |
AU662148B2 (en) * | 1991-04-10 | 1995-08-24 | Scripps Research Institute, The | Heterodimeric receptor libraries using phagemids |
US5733743A (en) * | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
US5383851A (en) * | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
US5807683A (en) * | 1992-11-19 | 1998-09-15 | Combichem, Inc. | Combinatorial libraries and methods for their use |
US5738996A (en) * | 1994-06-15 | 1998-04-14 | Pence, Inc. | Combinational library composition and method |
US5516637A (en) * | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
JP2978435B2 (en) * | 1996-01-24 | 1999-11-15 | チッソ株式会社 | Method for producing acryloxypropyl silane |
ES2221212T5 (en) * | 1997-10-02 | 2008-12-01 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | METHODS FOR THE MODULATION OF NEOVASCULARIZATION AND / OR THE GROWTH OF COLATERAL ARTERIES AND / OR OTHER ARTERIES FROM PREEXISTENT ARTERIOLARY CONNECTIONS. |
US7108852B2 (en) * | 2000-03-20 | 2006-09-19 | Warner-Lambert Company Llc | Methods of treating inflammation using antibodies to M-CSF |
US7455836B2 (en) * | 2000-05-08 | 2008-11-25 | The University Of Melbourne | Method of treatment and agents useful for same |
US7381801B2 (en) * | 2002-02-13 | 2008-06-03 | Ludwig Institute For Cancer Research | Chimerized GM-CSF antibodies |
US20050020619A1 (en) * | 2003-07-24 | 2005-01-27 | Patrick Betschmann | Thienopyridine kinase inhibitors |
-
2003
- 2003-11-05 GB GBGB0325836.5A patent/GB0325836D0/en not_active Ceased
-
2004
- 2004-11-03 ES ES04798381T patent/ES2733818T3/en active Active
- 2004-11-03 US US10/578,384 patent/US20070148172A1/en not_active Abandoned
- 2004-11-03 CA CA002543926A patent/CA2543926A1/en not_active Abandoned
- 2004-11-03 EP EP04798381.2A patent/EP1686970B1/en active Active
- 2004-11-03 AU AU2004289098A patent/AU2004289098B2/en not_active Ceased
- 2004-11-03 WO PCT/GB2004/004652 patent/WO2005046657A2/en active Application Filing
- 2004-11-03 JP JP2006537439A patent/JP2007510639A/en active Pending
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5932595A (en) * | 1995-12-20 | 1999-08-03 | Syntex (U.S.A.) Inc. | Matrix metalloprotease inhibitors |
WO1999043839A1 (en) * | 1998-02-27 | 1999-09-02 | The Trustees Of The University Of Pennsylvania | Vaccines, immunotherapeutics and methods for using the same |
WO2000067777A1 (en) * | 1999-05-07 | 2000-11-16 | Biofan Pty Ltd | A method of prophylaxis and treatment and agents useful therefor |
WO2001030381A2 (en) * | 1999-10-28 | 2001-05-03 | Hofbauer, Reinhold | Use of csf-1 inhibitors |
WO2002087496A2 (en) * | 2001-04-30 | 2002-11-07 | Cedars-Sinai Medical Center | Methods for inhibiting macrophage colony stimulating factor and c-fms-dependent cell signaling |
WO2003020698A2 (en) * | 2001-09-06 | 2003-03-13 | Prochon Biotech Ltd. | Protein tyrosine kinase inhibitors |
WO2005012226A1 (en) * | 2003-05-23 | 2005-02-10 | Mediquest Therapeutics, Inc. | Immunomodulation with novel pharmaceutical compositions |
WO2005010009A1 (en) * | 2003-07-24 | 2005-02-03 | Abbott Laboratories | Thienopyridine and furopyridine kinase inhibitors |
WO2005030124A2 (en) * | 2003-09-10 | 2005-04-07 | Warner-Lambert Company Llc | Antibodies to m-csf |
Non-Patent Citations (4)
Title |
---|
KLEBL F H ET AL: "Expression of macrophage-colony stimulating factor in normal and inflammatory bowel disease intestine" JOURNAL OF PATHOLOGY 2001 UNITED KINGDOM, vol. 195, no. 5, 2001, pages 609-615, XP002339478 ISSN: 0022-3417 * |
MAKIYAMA K ET AL: "Serum concentration of macrophage colony stimulating factor (M-CSF) in patients with inflammatory bowel disease" GASTROENTEROLOGIA JAPONICA 1993 JAPAN, vol. 28, no. 5, 1993, page 740, XP009051960 ISSN: 0435-1339 * |
MAROTTA F ET AL: "Disrupted mucosal barrier in quiescent ulcerative colitis: Effect of metronidazole and of a symbiotic preparation in a pilot cross-over study" CHINESE JOURNAL OF DIGESTIVE DISEASES 2003 AUSTRALIA, vol. 4, no. 4, 2003, pages 180-185, XP009051465 ISSN: 1443-9611 * |
See also references of EP1686970A2 * |
Cited By (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102702358B (en) * | 2008-03-14 | 2016-02-17 | 天士力创世杰(天津)生物制药有限公司 | For the antibody of CSF-1R |
US10287358B2 (en) | 2009-12-10 | 2019-05-14 | Hoffmann-La Roche Inc. | Antibodies against human CSF-1R and uses thereof |
US10077314B1 (en) | 2009-12-10 | 2018-09-18 | Hoffmann-La Roche Inc. | Antibodies against human CSF-1R and uses thereof |
US10072087B2 (en) | 2009-12-10 | 2018-09-11 | Hoffmann-La Roche Inc. | Antibodies against human CSF-1R and uses thereof |
US9879085B2 (en) | 2009-12-10 | 2018-01-30 | Hoffmann-La Roche Inc. | Antibodies against human CSF-1R and uses thereof |
US9663580B2 (en) | 2009-12-10 | 2017-05-30 | Hoffmann-La Roche Inc. | Antibodies against human CSF-1R and uses thereof |
WO2011070024A1 (en) | 2009-12-10 | 2011-06-16 | F. Hoffmann-La Roche Ag | Antibodies binding preferentially human csf1r extracellular domain 4 and their use |
US8999327B2 (en) | 2009-12-10 | 2015-04-07 | Hoffman-La Roche Inc. | Antibodies against human CSF-1R and uses thereof |
US9499625B2 (en) | 2009-12-10 | 2016-11-22 | Hoffmann-La Roche Inc. | Antibodies against human CSF-1R and uses thereof |
US9499624B2 (en) | 2009-12-10 | 2016-11-22 | Hoffmann-La Roche Inc. | Antibodies against human CSF-1R and uses thereof |
EP2949670A1 (en) | 2009-12-10 | 2015-12-02 | F. Hoffmann-La Roche AG | Antibodies binding preferentially human csf1r extracellular domain 4 and their use |
US9499626B2 (en) | 2009-12-10 | 2016-11-22 | Hoffmann-La Roche Inc. | Antibodies against human CSF-1R and uses thereof |
US9624302B2 (en) | 2010-03-05 | 2017-04-18 | Hoffmann-La Roche Inc. | Nucleic acids encoding antibodies against human CSF-1R |
US9988458B2 (en) | 2010-03-05 | 2018-06-05 | Hoffmann-La Roche Inc. | Antibodies against human CSF-1R and uses thereof |
US9221910B2 (en) | 2010-03-05 | 2015-12-29 | Hoffmann-La Roche Inc. | Antibodies against human CSF-1R |
WO2011107553A1 (en) | 2010-03-05 | 2011-09-09 | F. Hoffmann-La Roche Ag | Antibodies against human csf-1r and uses thereof |
US9169323B2 (en) | 2010-03-05 | 2015-10-27 | Hoffmann-La Roche Inc. | Antibodies against human CSF-1R |
WO2011131407A1 (en) | 2010-03-05 | 2011-10-27 | F. Hoffmann-La Roche Ag | Antibodies against human csf-1r and uses thereof |
US10030073B2 (en) | 2010-03-05 | 2018-07-24 | Hoffmann-La Roche Inc. | Antibodies against human CSF-1R and uses thereof |
US9617342B2 (en) | 2010-03-05 | 2017-04-11 | Hoffman-La Roche Inc. | Nucleic acids encoding antibodies against human CSF-1R and uses thereof |
WO2013011021A1 (en) | 2011-07-18 | 2013-01-24 | The University Of Melbourne | Use of c-fms antagonists |
US10005840B2 (en) | 2011-07-18 | 2018-06-26 | Morphosys Ag | Method for treatment of osteoarthritis with C-Fms antagonists |
US9243066B2 (en) | 2011-07-18 | 2016-01-26 | University Of Melbourne | Use of M-CSF antibodies in the treatment of osteoarthritis or pain |
US10336830B2 (en) | 2011-12-15 | 2019-07-02 | Hoffmann-La Roche Inc. | Antibodies against human CSF-1R and uses thereof |
WO2013087699A1 (en) | 2011-12-15 | 2013-06-20 | F. Hoffmann-La Roche Ag | Antibodies against human csf-1r and uses thereof |
US10023643B2 (en) | 2011-12-15 | 2018-07-17 | Hoffmann-La Roche Inc. | Antibodies against human CSF-1R and uses thereof |
WO2013132044A1 (en) | 2012-03-08 | 2013-09-12 | F. Hoffmann-La Roche Ag | Combination therapy of antibodies against human csf-1r and uses thereof |
US10081675B2 (en) | 2013-04-12 | 2018-09-25 | Morphosys Ag | Antibodies targeting M-CSF |
US9856316B2 (en) | 2013-04-12 | 2018-01-02 | Morphosys Ag | Antibodies targeting M-CSF |
WO2014173814A1 (en) | 2013-04-22 | 2014-10-30 | F. Hoffmann-La Roche Ag | Combination therapy of antibodies against human csf-1r and tlr9 agonist |
US9192667B2 (en) | 2013-04-22 | 2015-11-24 | Hoffmann-La Roche Inc. | Method of treating cancer by administering CSF-1R antibodies and a TLR9 agonist |
US11512133B2 (en) | 2013-09-12 | 2022-11-29 | Hoffmann-La Roche Inc. | Methods for treating colon cancer or inhibiting cell proliferation by administering a combination of antibodies against human CSF-1R and antibodies against human PD-L1 |
CN107810012A (en) * | 2015-06-02 | 2018-03-16 | 豪夫迈·罗氏有限公司 | Use the composition and method of the anti-Antybody therapy sacred diseases of IL 34 |
WO2016196679A1 (en) * | 2015-06-02 | 2016-12-08 | Genentech, Inc. | Compositions and methods for using anti-il-34 antibodies to treat neurological diseases |
EP3108897A1 (en) | 2015-06-24 | 2016-12-28 | F. Hoffmann-La Roche AG | Antibodies against human csf-1r for use in inducing lymphocytosis in lymphomas or leukemias |
WO2018036852A1 (en) | 2016-08-25 | 2018-03-01 | F. Hoffmann-La Roche Ag | Intermittent dosing of an anti-csf-1r antibody in combination with macrophage activating agent |
US11542335B2 (en) | 2016-08-25 | 2023-01-03 | Hoffmann-La Roche Inc. | Method of treating cancer in a patient by administering an antibody which binds colony stimulating factor-1 receptor (CSF-1R) |
WO2018115051A1 (en) | 2016-12-22 | 2018-06-28 | F. Hoffmann-La Roche Ag | Treatment of tumors with an anti-csf-1r antibody in combination with an anti-pd-l1 antibody after failure of anti-pd-l1/pd1 treatment |
US11498968B2 (en) | 2016-12-22 | 2022-11-15 | Hoffmann-La Roche Inc. | Treatment of tumors with an anti-CSF-1R antibody in combination with an anti-PD-L1 antibody after failure of anti-PD-L1/PD1 treatment |
WO2022238386A1 (en) | 2021-05-10 | 2022-11-17 | Institut Curie | Methods for the treatment of cancer, inflammatory diseases and autoimmune diseases |
Also Published As
Publication number | Publication date |
---|---|
WO2005046657A3 (en) | 2005-11-03 |
ES2733818T3 (en) | 2019-12-03 |
US20070148172A1 (en) | 2007-06-28 |
JP2007510639A (en) | 2007-04-26 |
CA2543926A1 (en) | 2005-05-26 |
GB0325836D0 (en) | 2003-12-10 |
AU2004289098B2 (en) | 2010-07-01 |
EP1686970B1 (en) | 2019-04-10 |
EP1686970A2 (en) | 2006-08-09 |
AU2004289098A1 (en) | 2005-05-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1686970B1 (en) | Use of an inhibitor of CSF-1 activity for the treatment of Crohn's disease or ulcerative colitis | |
US7931900B2 (en) | Method for the treatment of multiple sclerosis by inhibiting IL-17 activity | |
US8304200B2 (en) | Methods for obtaining antibodies | |
JP6618471B2 (en) | Methods for the treatment of fibrotic diseases | |
TWI327070B (en) | Modulators of p-selectin glycoprotein ligand 1 | |
JP6851322B2 (en) | How to treat neurological disorders | |
CA2402477A1 (en) | Eosinophil-specific apoptosis inducer | |
US7771969B2 (en) | Methods for obtaining antibodies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004798381 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2543926 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006537439 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004289098 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2004289098 Country of ref document: AU Date of ref document: 20041103 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004289098 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2004798381 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007148172 Country of ref document: US Ref document number: 10578384 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10578384 Country of ref document: US |